Theratechnologies (THTX) News Today → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free THTX Stock Alerts $1.36 -0.02 (-1.45%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTheratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholdersglobenewswire.com - April 15 at 4:15 PMFY2024 Earnings Estimate for Theratechnologies Inc. Issued By Cantor Fitzgerald (NASDAQ:THTX)americanbankingnews.com - April 15 at 1:34 AMTheratechnologies Inc. (THTX) Q1 2024 Earnings Call Transcriptseekingalpha.com - April 11 at 10:34 PMTheratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferenceglobenewswire.com - April 11 at 7:30 AMTHTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024investorplace.com - April 10 at 1:04 PMTheratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024globenewswire.com - April 10 at 7:30 AMTheratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024globenewswire.com - April 10 at 7:30 AMTheratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platformglobenewswire.com - April 8 at 4:30 PMTheratechnologies Appoints Elina Tea to its Board of Directorsglobenewswire.com - April 5 at 11:00 AMTheratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Updateglobenewswire.com - April 3 at 7:30 AMTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) Platformstockhouse.com - March 30 at 4:15 PMTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platformglobenewswire.com - March 28 at 7:30 AMTheratechnologies shifts focus, phases down preclinical researchinvesting.com - March 24 at 9:04 PMTheratechnologies Announces Update on its Preclinical Oncology Research Programglobenewswire.com - March 22 at 9:36 AMTheratechnologies Appoints Jordan Zwick to its Board of Directorsglobenewswire.com - March 21 at 8:00 PMTheratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancerglobenewswire.com - March 21 at 7:30 AMTheratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeauglobenewswire.com - February 29 at 4:34 PMTheratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDAglobenewswire.com - February 27 at 7:30 AMTheratechnologies: Fiscal Q4 Earnings Snapshotwashingtonpost.com - February 21 at 11:52 AMTheratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidanceglobenewswire.com - February 21 at 7:30 AMTheratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Actionglobenewswire.com - February 20 at 7:30 AMTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancerfinance.yahoo.com - February 15 at 8:06 AMTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancerglobenewswire.com - February 15 at 7:30 AMmarketbeat.com - January 24 at 6:58 AMTheratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Applicationfinance.yahoo.com - January 23 at 7:52 AMUpcoming FDA Decision: How likely is approval for EGRIFTA MDV?msn.com - January 19 at 1:30 PMWill This Dual-Listed Bio-Pharma Catch New Year Action?theglobeandmail.com - January 6 at 8:09 PMTheratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDAfinance.yahoo.com - January 2 at 9:21 AMTheratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDAfinance.yahoo.com - January 2 at 9:21 AMTheratechnologies Files SBLA For Trogarzo Intramuscular Method Of Administration With FDAmarkets.businessinsider.com - January 2 at 9:21 AMTheratechnologies Files SBLA For Trogarzo Intramuscular Method Of Administration With FDAmarkets.businessinsider.com - January 2 at 9:21 AMTheratechnologies files for $100M mixed securities shelfmsn.com - December 21 at 5:20 PMTheratechnologies files for $100M mixed securities shelfmsn.com - December 21 at 5:20 PMTheratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statementfinance.yahoo.com - December 21 at 5:20 PMFDA Approves Theratechnologies' Trogarzo 90-second IV Push Loading Dosemarkets.businessinsider.com - December 13 at 9:48 AMFDA Approves Theratechnologies' Trogarzo 90-second IV Push Loading Dosemarkets.businessinsider.com - December 13 at 9:48 AMTheratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dosemarkets.businessinsider.com - December 13 at 9:48 AMTheratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placementfinance.yahoo.com - October 31 at 1:58 PMTheratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placementfinance.yahoo.com - October 26 at 8:45 AMTheratechnologies Revises Fiscal Revenue Target Amid Continuity Concernsinvesting.com - October 26 at 12:08 AMTheratechnologies Announces Operational Updatefinance.yahoo.com - October 24 at 8:51 AMTheratechnologies' Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIVfinancialpost.com - October 19 at 10:42 AMTheratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIVfinance.yahoo.com - October 19 at 10:42 AMTheratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathonstockhouse.com - October 16 at 8:42 AMHold Rating on Theratechnologies Amid Mixed Trogarzo Performance and Future Growth Potentialmarkets.businessinsider.com - October 16 at 8:42 AMTheratechnologies says Trogarzo IM method of administration study did not meet primary endpointmsn.com - October 13 at 9:13 AMTheratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancerfinance.yahoo.com - October 12 at 8:00 AMTheratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLAfinance.yahoo.com - October 4 at 10:01 AMEarnings Outlook For Theratechnologiesbenzinga.com - September 25 at 1:54 PMTheratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facilityfinance.yahoo.com - September 25 at 8:54 AM Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Bitcoin Rockets To Record High But Buy THIS Instead (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring… >>Click here to find out what it is. THTX Media Mentions By Week THTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. THTX News Sentiment▼1.000.44▲Average Medical News Sentiment THTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. THTX Articles This Week▼01▲THTX Articles Average Week Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CASI News Today ACXP News Today VYNE News Today IPA News Today VIRX News Today NRXP News Today FBIO News Today DARE News Today APRE News Today LEXX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:THTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
